First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia ...
MiNK Therapeutics (INKT) announced data from two poster presentations at the Society for Immunotherapy of Cancer’s 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK ...
Thank you, Stefanie. For those new to MiNK Therapeutics, we are advancing a clinically validated allogeneic invariant natural killer T cell platform, one that is fundamentally differentiated in its ...
T-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential ...
(RTTNews) - MiNK Therapeutics (INKT), a clinical-stage company, said new translational data supporting the role of invariant natural killer T or iNKT cells in idiopathic pulmonary fibrosis or IPF were ...
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE)-- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to ...
Good morning, and welcome to MiNK Therapeutics' Second Quarter 2025 Conference Call and Webcast. [Operator Instructions] Please note that this event is being recorded. If anyone has any objections, ...
Allogeneic invariant natural killer T cells (allo-iNKTs) from a healthy donor have been shown to have therapeutic effects in treatment-resistant cancers and improve survival from COVID-19-related ...
MiNK Therapeutics, Inc. (NASDAQ:INKT) shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. What Happened: On ...
MiNK Therapeutics, Inc. (NASDAQ:INKT) stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million as per data from Benzinga Pro. The clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results